Oppenheimer Asset Management Inc. reduced its stake in iRhythm Technologies, Inc. (NASDAQ:IRTC – Get Rating) by 7.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,996 shares of the company’s stock after selling 684 shares during the period. Oppenheimer Asset Management Inc.’s holdings in iRhythm Technologies were worth $749,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of IRTC. US Bancorp DE boosted its stake in iRhythm Technologies by 3.7% in the first quarter. US Bancorp DE now owns 4,012 shares of the company’s stock valued at $632,000 after acquiring an additional 144 shares during the period. MetLife Investment Management LLC boosted its stake in iRhythm Technologies by 49.2% in the first quarter. MetLife Investment Management LLC now owns 15,778 shares of the company’s stock valued at $2,485,000 after acquiring an additional 5,205 shares during the period. BlackRock Inc. boosted its stake in iRhythm Technologies by 0.4% in the first quarter. BlackRock Inc. now owns 2,093,147 shares of the company’s stock valued at $329,607,000 after acquiring an additional 8,440 shares during the period. Dimensional Fund Advisors LP boosted its stake in iRhythm Technologies by 4.0% in the first quarter. Dimensional Fund Advisors LP now owns 68,492 shares of the company’s stock valued at $10,783,000 after acquiring an additional 2,603 shares during the period. Finally, Vontobel Holding Ltd. acquired a new position in iRhythm Technologies in the first quarter valued at approximately $248,000. 98.96% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at iRhythm Technologies
In other iRhythm Technologies news, EVP Daniel G. Wilson sold 4,000 shares of the company’s stock in a transaction on Wednesday, March 29th. The stock was sold at an average price of $125.00, for a total value of $500,000.00. Following the transaction, the executive vice president now owns 35,337 shares of the company’s stock, valued at $4,417,125. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other iRhythm Technologies news, EVP Daniel G. Wilson sold 4,000 shares of the company’s stock in a transaction on Wednesday, March 29th. The stock was sold at an average price of $125.00, for a total value of $500,000.00. Following the transaction, the executive vice president now owns 35,337 shares of the company’s stock, valued at $4,417,125. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Daniel G. Wilson sold 1,726 shares of the company’s stock in a transaction on Tuesday, February 28th. The shares were sold at an average price of $117.84, for a total value of $203,391.84. Following the completion of the transaction, the executive vice president now directly owns 40,759 shares in the company, valued at approximately $4,803,040.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 15,317 shares of company stock valued at $1,831,058. Corporate insiders own 0.43% of the company’s stock.
iRhythm Technologies Price Performance
iRhythm Technologies (NASDAQ:IRTC – Get Rating) last posted its quarterly earnings results on Thursday, February 23rd. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.04). The company had revenue of $112.62 million during the quarter, compared to the consensus estimate of $110.62 million. iRhythm Technologies had a negative net margin of 28.27% and a negative return on equity of 35.85%. Equities research analysts anticipate that iRhythm Technologies, Inc. will post -2.82 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on IRTC shares. Wells Fargo & Company assumed coverage on iRhythm Technologies in a research note on Tuesday, February 7th. They issued an “overweight” rating and a $150.00 target price for the company. BTIG Research boosted their price objective on iRhythm Technologies from $168.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, April 17th. StockNews.com upgraded iRhythm Technologies from a “sell” rating to a “hold” rating in a research report on Wednesday, March 22nd. Needham & Company LLC boosted their price objective on iRhythm Technologies from $133.00 to $151.00 in a research report on Friday. Finally, Citigroup boosted their price objective on iRhythm Technologies from $130.00 to $135.00 in a research report on Friday. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $154.40.
iRhythm Technologies Company Profile
iRhythm Technologies, Inc is a digital healthcare company, which engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N.
Featured Articles
- Get a free copy of the StockNews.com research report on iRhythm Technologies (IRTC)
- It’s Time To Check Into Booking.Com
- Shopify Delivers Growth And Efficiency; Shares Surge
- Advanced Micro Devices Bullish Reversal Is Still In Play
- Broadcom Shares Trade In Tight Range Ahead Of Q2 Earnings Report
- An Opportunity To Buy Starbucks Is Knocking On The Door
Receive News & Ratings for iRhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
